Alina Renz

University of Tübingen

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (3)

Monika Schütz

University Hospital Tübingen

GERMANY

View details

Andreas Dräger

Junior Professor

Eberhard Karls Universität Tübingen

GERMANY

View details

Julia-Stefanie Frick

Principle Investigator, Associate Professor

Eberhard Karls Universität Tübingen

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alina Renz

Research Interests

Explore related searches

Contact this professor

Articles (12)

Genome-scale metabolic model of Staphylococcus epidermidis ATCC 12228 matches in vitro conditions

Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses

SBOannotator: a Python tool for the automated assignment of systems biology ontology terms

New workflow predicts drug targets against SARS-CoV-2 via metabolic changes in infected cells

Genome-scale model of Pseudomonas aeruginosa metabolism unveils virulence and drug potentiation

A Computational Model of Bacterial Population Dynamics in Gastrointestinal Yersinia enterocolitica Infections in Mice

An updated genome-scale metabolic network reconstruction of Pseudomonas aeruginosa PA14 to characterize mucin-driven shifts in bacterial metabolism

Curating and comparing 114 strain-specific genome-scale metabolic models of Staphylococcus aureus

Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target

First Genome-Scale Metabolic Model of Dolosigranulum pigrum Confirms Multiple Auxotrophies

Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.

FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2.

Collaborators (3)

Monika Schütz

Andreas Dräger

Julia-Stefanie Frick

Make your next move.